LLY : Analysis & Opinions

  1. Navient Rewards Shareholders with New Buyback Program - Analyst ...

    December 16, 2014
    Navient Corporation (NAVI) announced a new share repurchase program for up to $1.0 billion of its outstanding common stock.
  2. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  3. These Companies Could Run Out of Cash Without Tax Reform

    November 12, 2014
    The wave of Republican victories in mid-term elections blew past everyone's expectations and sparked a rally in the markets. ...
  4. Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little blue pill.

    Why There's Far More To Pfizer Than Viagra

    July 30, 2014
    Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little ...
  5. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  6. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  7. My Favorite Pharma Stock Is Stronger Than Ever

    January 17, 2014
    What do you call 10,000 baby boomers turning 65 every day for the next 20 years? If you're a big pharmaceutical company, ...
  8. The Simple Win-Win Strategy For Taming Risk In Your Portfolio

    January 17, 2014
    Risk is a fundamental part of investing. It might be easiest to understand by using bonds as an example.#-ad_banner-#​With ...
  9. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  10. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  11. Positive Phase III Data on Sanofi's U300 - Analyst Blog

    June 24, 2013
    Sanofi announced encouraging data from two phase III studies evaluating U300.
  12. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  13. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  14. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  15. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  16. Pfizer's Lyrica Scores in Study - Analyst Blog

    November 21, 2012
    Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). Results ...
  17. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  18. Eli Lilly Among Healthcare's Biggest Movers on August 27, 2012

    August 27, 2012
    The market is on the rise this morning. The Nasdaq is up 0.5%; the S&P 500 has risen 0.3%; and the Dow has climbed 0.1%. ...
  19. Healthcare Stocks, Including Eli Lilly, Making Big Moves on August ...

    August 24, 2012
    The Nasdaq has increased 0.6%, the S&P 500 has risen 0.5% and the Dow has moved up 0.6% on a good day for the market ...
  20. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  21. Four S&P Stocks With A P/E Ratio Under 12

    June 27, 2012
    Using the P/E ratio of a stock can be a great step to finding value.
  22. Stocks Pay Huge Dividends

    May 31, 2012
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  23. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  24. Four S&P Stocks With Under A 12 P/E Ratio

    February 14, 2012
    There are still quality blue chip-like names that offer decent valuations and, in some cases, excellent yields.
  25. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  26. How Long Will The Dividend Stock Craze Last?

    January 11, 2012
    2011 saw some stocks yield surprisingly high dividends, but should you wait before investing in these companies?
  27. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  28. 5 Dividend Darlings

    October 20, 2011
    Strong dividend payers could form the best defense in an unsure market.
  29. What Is Walgreen's Next Trick?

    September 30, 2011
    Walgreen is doing okay today, but tomorrow is a much bigger question.
  30. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  31. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  32. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  33. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  34. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  35. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  36. On The Hunt For Dividend Stocks

    February 15, 2011
    Interested investors can find dividends in a variety of shapes and sizes.
  37. Top 3 Sectors For Value Investors

    February 8, 2011
    As the U.S. economy has recovered, so have the equity markets. Learn the best-value sectors that investors should focus on. ...
  38. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  39. Undervalued Large Cap Stocks

    December 30, 2010
    undervalued stocks
  40. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  41. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  42. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  43. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  44. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
  45. Best Dividend Stocks

    September 17, 2010
    These dividend stocks should add value to any portfolio.
  46. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  47. 5-Star Dividend Stocks

    July 22, 2010
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  48. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma. ...
  49. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  50. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament. ...
  51. Four S&P Stocks Under An 8 P/E Ratio

    April 2, 2010
    Forget about capturing returns from last year's stock prices. Yet even today, quality blue chip-like names offer decent valuations ...
  52. High Yield Bets For The Conservative Investor

    July 24, 2009
    High dividends and long-term dependability make it worth getting involved with these companies.
  53. Dividend Divas For July 14

    July 14, 2009
    Companies that pay a high dividend show their commitment to returning money to shareholders. Here we drill down into the ...
  54. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide. ...
  55. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  56. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  57. Profit Locally, Invest Globally

    June 30, 2008
    As the U.S. equity market drops, overseas stocks appear more and more attractive. We examine a trio of ADRs ready to grow. ...
  58. Pfizer's Exubera Pflops (PFE)

    October 25, 2007
    Pfizer took a $2.8 billion hit when it cancelled Exubera from its product line - is the worst now over, or is there more ...
  59. Up on Amgen (AMGN)

    April 30, 2007
    Amgen shares are in a rut, and that could signal opportunity for investors.
  60. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  61. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider. ...
Trading Center